Duopharma Biotech (DBB MK): Strong Performance and Positive Outlook
Duopharma Biotech: Strong Performance and Positive Outlook RHB Small Cap Asean Research 22 August 2025 Duopharma Biotech (DBB MK): Strong Performance and Positive Outlook On a Solid Footing; Maintain BUY Shariah Compliant Malaysia Results Review Consumer Non-cyclical | Pharmaceuticals Keep BUY and DCF-derived MYR1.56 TP, 18% upside and c.2% FY25F yield. Duopharma Biotech booked 2Q25…
